Geron (GERN) Competitors $2.56 -0.23 (-8.24%) Closing price 02/14/2025 04:00 PM EasternExtended Trading$2.58 +0.02 (+0.98%) As of 02/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends GERN vs. ALKS, IONS, FOLD, LGND, BCRX, DVAX, MNKD, CLDX, NVAX, and INVAShould you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Dynavax Technologies (DVAX), MannKind (MNKD), Celldex Therapeutics (CLDX), Novavax (NVAX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry. Geron vs. Alkermes Ionis Pharmaceuticals Amicus Therapeutics Ligand Pharmaceuticals BioCryst Pharmaceuticals Dynavax Technologies MannKind Celldex Therapeutics Novavax Innoviva Alkermes (NASDAQ:ALKS) and Geron (NASDAQ:GERN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends. Do analysts rate ALKS or GERN? Alkermes presently has a consensus target price of $37.25, indicating a potential upside of 3.79%. Geron has a consensus target price of $7.25, indicating a potential upside of 183.20%. Given Geron's stronger consensus rating and higher possible upside, analysts clearly believe Geron is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.67Geron 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.09 Which has more risk & volatility, ALKS or GERN? Alkermes has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Do insiders and institutionals believe in ALKS or GERN? 95.2% of Alkermes shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 4.9% of Alkermes shares are held by insiders. Comparatively, 3.1% of Geron shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings & valuation, ALKS or GERN? Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.66B3.49$355.76M$1.9518.41Geron$240K6,448.00-$184.13M-$0.32-8.00 Does the MarketBeat Community prefer ALKS or GERN? Alkermes received 207 more outperform votes than Geron when rated by MarketBeat users. Likewise, 70.52% of users gave Alkermes an outperform vote while only 70.07% of users gave Geron an outperform vote. CompanyUnderperformOutperformAlkermesOutperform Votes70170.52% Underperform Votes29329.48% GeronOutperform Votes49470.07% Underperform Votes21129.93% Is ALKS or GERN more profitable? Alkermes has a net margin of 22.15% compared to Geron's net margin of -682.48%. Alkermes' return on equity of 24.92% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Alkermes22.15% 24.92% 14.55% Geron -682.48%-67.53%-45.46% Does the media prefer ALKS or GERN? In the previous week, Alkermes had 38 more articles in the media than Geron. MarketBeat recorded 41 mentions for Alkermes and 3 mentions for Geron. Geron's average media sentiment score of 0.92 beat Alkermes' score of 0.48 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 7 Very Positive mention(s) 7 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Geron 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAlkermes beats Geron on 13 of the 19 factors compared between the two stocks. Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.55B$6.84B$5.76B$9.22BDividend YieldN/A2.90%5.27%4.00%P/E Ratio-8.009.7126.2219.45Price / Sales6,448.00290.45456.5777.34Price / CashN/A75.4646.0638.90Price / Book5.575.537.355.05Net Income-$184.13M$123.46M$3.19B$222.81M7 Day Performance-9.22%1.37%1.69%1.29%1 Month Performance-11.42%2.09%4.13%1.52%1 Year Performance27.36%1.28%22.24%16.53% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron3.3966 of 5 stars$2.56-8.2%$7.25+183.2%+27.4%$1.55B$240,000.00-8.0070High Trading VolumeALKSAlkermes3.4463 of 5 stars$31.33-0.8%$36.00+14.9%+11.5%$5.08B$1.66B16.092,100Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionIONSIonis Pharmaceuticals4.0017 of 5 stars$31.21-0.6%$60.65+94.3%-30.1%$4.93B$788M-12.81800Short Interest ↑FOLDAmicus Therapeutics4.0052 of 5 stars$9.61-0.5%$16.88+75.7%-29.0%$2.88B$399.36M-28.35480News CoverageLGNDLigand Pharmaceuticals4.1543 of 5 stars$115.46+0.2%$147.00+27.3%+62.9%$2.18B$131.31M45.9880News CoveragePositive NewsBCRXBioCryst Pharmaceuticals4.0491 of 5 stars$8.54-2.1%$15.50+81.6%+52.9%$1.78B$331.41M-14.11530DVAXDynavax Technologies4.2493 of 5 stars$13.26+0.8%$23.00+73.5%+3.3%$1.75B$232.28M102.12350MNKDMannKind2.898 of 5 stars$5.61-0.4%$9.21+64.4%+48.5%$1.55B$267.20M80.50400Gap UpCLDXCelldex Therapeutics1.5509 of 5 stars$21.58-4.0%$62.25+188.5%-40.7%$1.43B$6.88M-8.37150Upcoming EarningsAnalyst RevisionNews CoverageNVAXNovavax4.1622 of 5 stars$8.19+0.7%$17.83+117.9%+96.9%$1.31B$983.71M-3.631,543INVAInnoviva2.9541 of 5 stars$18.21-1.1%N/A+14.0%$1.14B$310.46M26.41100Short Interest ↓News Coverage Related Companies and Tools Related Companies ALKS Competitors IONS Competitors FOLD Competitors LGND Competitors BCRX Competitors DVAX Competitors MNKD Competitors CLDX Competitors NVAX Competitors INVA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GERN) was last updated on 2/18/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredAre We Headed for a Market Implosion?The world's biggest tech companies are silently sounding the alarm. While everyday investors keep piling in...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.